Kosaraju Sridhar's Form 4 filing
10x Genomics, Inc. (TXG) · filed Oct 27, 2021
- Accession no.
- 0001567619-21-018801
- Filed
- Oct 27, 2021
- Trade date
- Oct 25, 2021
- Filing delay
- 2 days
- Rule 10b5-1 plan
- Not on the form (before 2023)
This filing lists 5 non-derivative transactions. Open-market sales total $249.5K. It was filed 2 days after the trade.
Reporting owners
A Form 4 can have several reporting owners, such as a person and a fund they control. Trade tables show the first one.
| Owner | Relationship to the company |
|---|---|
| Kosaraju SridharCIK 0001651325 | Director |
Non-derivative securities (Table I)
Acquisitions and disposals of common stock and similar shares, one row per line on the filing.
| Trade date | Security | Transaction | Shares | Price | Value | Shares after | Ownership | Flags |
|---|---|---|---|---|---|---|---|---|
| Oct 25, 2021 | Class A Common Stock | SSaleDisposed | −100 | $163.85 | −$16,385 | 7,400 | Indirect | |
| Oct 25, 2021 | Class A Common Stock | SSaleDisposed | −600 | $165.14F3 | −$99,084 | 6,800 | Indirect | |
| Oct 25, 2021 | Class A Common Stock | SSaleDisposed | −400 | $166.60F4 | −$66,640 | 6,400 | Indirect | |
| Oct 25, 2021 | Class A Common Stock | SSaleDisposed | −100 | $167.63 | −$16,763 | 6,300 | Indirect | |
| Oct 25, 2021 | Class A Common Stock | SSaleDisposed | −300 | $168.68F5 | −$50,604 | 6,000 | Indirect |
Footnotes and remarks
Livermore keeps the footnotes that transaction prices refer to, all footnotes of amendments (Form 4/A) and the filing's remarks. Other footnotes, such as how indirect holdings are held or the details of a trading plan, are only in the original on SEC EDGAR.
- F3
This transaction was executed in multiple trades at prices ranging from $164.57 to $165.54. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price.
Referenced by the price of 1 transaction in Table I.
- F4
This transaction was executed in multiple trades at prices ranging from $166.23 to $167.145. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price.
Referenced by the price of 1 transaction in Table I.
- F5
This transaction was executed in multiple trades at prices ranging from $168.49 to $168.78. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price.
Referenced by the price of 1 transaction in Table I.